VBIO · Valion Bio, Inc. · Executive Compensation
$1.20
+0.01 (+0.84%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current cash levels and burn rate, amongst other things, the Company believes its cash and financial resources may be insufficient to meet the Company's anticipated needs for the twelve months following the date of issuance of the financial statements for the six months ended June 30, 2026, included elsewhere in this Report, which raises substantial doubt about the Company's ability to continue as a going concern within one year from the issuance date of the financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.02M
Shares
887,590
Volume · Oct 20
59.72K
Avg daily vol (36 sessions)
2.39M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael K. Handley | CEO | $590,694 |
| Michael Handley | Chief Executive Officer and Director; Former Chief Operating Officer | $590,694 |
| Jennifer Ernst | Former Chief Executive Officer and Director | $396,767 |
| Lisa Wolf | Chief Financial Officer | $333,977 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Blake Gurfein | Chief Scientific Officer | $486,524 |
| Jennifer Ernst | Former Chief Executive Officer and Director | $430,456 |
| Kimberly Bambach | Former Interim Chief Financial Officer | $214,325 |
| Lisa Wolf | Chief Financial Officer | $65,119 |
| Michael K. Handley | CEO | — |
| Michael Handley | Chief Executive Officer and Director; Former Chief Operating Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Blake Gurfein | Chief Scientific Officer | $392,706 |
| Jennifer Ernst | CEO and Director | $313,947 |
| Ryan Sabia | Former Chief Operating Officer | $285,241 |
| Kimberly Bambach | Former Interim Chief Financial Officer | $197,755 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jennifer Ernst | CEO and Director | $419,221 |
| Veronica Cai | CFO | $406,797 |
| Blake Gurfein | Chief Scientific Officer | $384,902 |
| Ryan Sabia | Former Chief Operating Officer | $337,433 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Blake Gurfein | Chief Scientific Officer | $442,920 |
| Jennifer Ernst | CEO and Director | $249,452 |
| Veronica Cai | CFO | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Blake Gurfein | Chief Scientific Officer | $242,526 |
| Jennifer Ernst | CEO and Director | $197,442 |
| Briana Benz | CFO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jared Malbin | Chair of the Board’s Audit and Risk Committee | Appointed | 2026-09-23 |
| Thomas Jensen | Chair of the Board | Appointed | 2026-09-23 |
| Sheryle Bolton | Board | Resigned | 2026-09-23 |
| Dean Zikria | Interim Chief Executive Officer | Appointed | 2026-09-23 |
| Thomas Jensen | member of the Board | Appointed | 2026-09-01 |
| Jared Malbin | member of the board of directors | Appointed | 2026-09-01 |
| Michael K. Handley | Chief Executive Officer | Terminated | 2026-08-17 |
| Lisa Wolf | Chief Operating Officer | Appointed | 2026-08-17 |
| Dean Zikria | Class II director | Appointed | 2026-06-03 |
| Melinda Lackey | General Counsel and Senior Vice President of Legal Affairs | Appointed | 2026-05-04 |
| Jennifer Ernst | member of the Board of Directors | Resigned | 2026-03-04 |
| Michael K. Handley | member of the board of directors | Appointed | 2026-03-04 |
| Jennifer Ernst | Chief Executive Officer | Resigned | 2026-03-04 |
| Michael K. Handley | Chief Executive Officer | Appointed | 2026-03-04 |
| Lisa Wolf | permanent Chief Financial Officer | Appointed | 2025-07-07 |
| Michael K. Handley | President of Tivic Biopharma | Appointed | 2025-02-24 |
| Michael K. Handley | Chief Operating Officer of Tivic Health | Appointed | 2025-02-24 |
| Michael Handley | President of the Company’s Tivic Biopharma division | Appointed | 2025-02-24 |
| Michael Handley | Chief Operating Officer | Appointed | 2025-02-24 |
| Lisa Wolf | interim Chief Financial Officer and Principal Financial and Principal Accounting Officer | Appointed | 2024-09-13 |
| Kimberly Bambach | interim Chief Financial Officer | Resigned | 2024-09-13 |
| Sheryle Bolton | Class III director | Appointed | 2024-08-13 |
| Jennifer Ernst | Class III director | Appointed | 2024-08-13 |
| Karen Drexler | director | Resigned | 2024-06-18 |
| Christina Valauri | director | Appointed | 2024-06-18 |
Leadership
- Dean Zikria CEO, Board Member
- Jennifer Ernst CEO, Board Member
- Michael K. Handley CEO, COO, Board Member
- Thomas Jensen Chairman, Board Member
- Kimberly Bambach CFO, Chief Accounting Officer
- Lisa Wolf CFO, COO
- Michael Handley COO
- Melinda Lackey General Counsel
- Christina Valauri Board Member
- Jared Malbin Board Member